{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T02:21:37Z","timestamp":1786760497971,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>\n                    We report a 38-year-old man with radio-iodine refractory papillary thyroid carcinoma (RAIR PTC) who experienced significant relief from symptoms and showed a positive biochemical response after undergoing a single cycle of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI-2286 therapy. A pretreatment\n                    <jats:sup>99m<\/jats:sup>\n                    Tc-FAPI-46 scan showed diffuse uptake throughout both lungs and subsequent serial post-treatment scans demonstrated sustained uptake in pulmonary metastases. After treatment, there was a significant decline in serum thyroglobulin levels, accompanied by a remarkable improvement in symptoms, leading to near-complete resolution. This case highlights the potential of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI-2286 therapy as an effective treatment option for RAIR PTC patients.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000005728","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T21:46:43Z","timestamp":1743716803000},"page":"e315-e316","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["177Lu-FAPI-2286 Therapy in a Patient With Radio-iodine Refractory Papillary Thyroid Carcinoma: A Favorable Clinical and Biochemical Response"],"prefix":"10.1097","volume":"50","author":[{"given":"Nasrin","family":"Raeisi","sequence":"first","affiliation":[{"name":"Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Saber Tanha","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hossein","family":"Gozashti","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Kiamanesh","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-8903","authenticated-orcid":false,"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"R1-20250403","doi-asserted-by":"crossref","first-page":"1071022","DOI":"10.3389\/fnume.2022.1071022","article-title":"Case report: regaining radioiodine uptake following PRRT in radioiodine-refractory thyroid cancer: a new re-differentiation strategy?","volume":"2","author":"Hadad","year":"2023","journal-title":"Front Nucl Med"},{"key":"R2-20250403","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1053\/j.semnuclmed.2024.01.011","article-title":"Theranostics of thyroid cancer","volume":"54","author":"Giovanella","year":"2024","journal-title":"Semin Nucl Med"},{"key":"R3-20250403","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/RLU.0000000000004260","article-title":"FAP-targeted radionuclide therapy of advanced radioiodine-refractory differentiated thyroid cancer with multiple cycles of 177Lu-FAPI-46","volume":"47","author":"Fu","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R4-20250403","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-human, dose-escalation study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R5-20250403","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/RLU.0000000000003730","article-title":"68Ga-FAPI PET\/CT Versus 18F-FDG PET\/CT for detecting metastatic lesions in a Case cf radioiodine-refractory differentiated thyroid cancer","volume":"46","author":"Fu","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R6-20250403","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/RLU.0000000000005301","article-title":"68Ga-FAPI-RGD PET\/CT detected skull metastasis better than 18F-FDG in a patient with radioiodine-refractory differentiated thyroid cancer","volume":"49","author":"Chen","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R7-20250403","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1148\/radiol.212430","article-title":"68 Ga fibroblast activation protein inhibitor PET\/CT in the detection of metastatic thyroid cancer: comparison with 18 F-FDG PET\/CT","volume":"304","author":"Fu","year":"2022","journal-title":"Radiology"},{"key":"R8-20250403","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1097\/RLU.0000000000005031","article-title":"FAPI PET missed widespread bone marrow metastases from follicular thyroid cancer that were detected by FDG PET","volume":"49","author":"Shi","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R9-20250403","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1097\/RLU.0000000000003489","article-title":"Fibroblast activation protein inhibitor PET\/CT","volume":"46","author":"Sharma","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R10-20250403","article-title":"FAPI PET\/CT provides higher uptake and better target to back ground in recurrent and metastatic tumors of patients with Iodine refractory papillary thyroid cancer compared with FDG PET CT","author":"Nourbakhsh","year":"2024","journal-title":"Nuklearmedizin"},{"key":"R11-20250403","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/cancers16040839","article-title":"FAPi-based agents in thyroid cancer: a new step towards diagnosis and therapy? A systematic review of the literature","volume":"16","author":"Guglielmo","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R12-20250403","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/RLU.0000000000003569","article-title":"68Ga-FAPI PET\/CT in thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy","volume":"46","author":"Fu","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R13-20250403","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13550-023-01060-8","article-title":"Advancements in theranostic applications: exploring the role of fibroblast activation protein inhibition tracers in enhancing thyroid health assessment","volume":"13","author":"Wang","year":"2023","journal-title":"EJNMMI Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000005728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:53:10Z","timestamp":1786035190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000005728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005728","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"2024-10-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}